

Clinical Considerations in Lung and Head & Neck Cancers: Where Are We Now and Where Are We Going?

Invitation

Dear Colleagues,

On behalf of Bristol-Myers Squibb, it is my pleasure to invite you to an industry satellite symposium titled “Clinical Considerations in Lung and Head & Neck Cancers: Where Are We Now and Where Are We Going?” as part of the ESMO 2017 Congress taking place in Madrid, Spain.

Immuno-oncology (I-O) therapies mobilize the body’s own immune system to fight against cancer, and have demonstrated clinical benefits for patients with lung and head & neck cancers. In this symposium, we will review the ever-evolving I-O treatment landscape and highlight exciting new avenues of research seeking to enhance the clinical impact of I-O in these cancers.

Already, single-agent I-O therapy has become a mainstay in the treatment paradigm for patients with advanced non-small cell lung cancer (NSCLC), having demonstrated impressive long-term survival outcomes in the second-line setting. I-O monotherapy has also benefited patients with recurrent or metastatic head & neck cancer, who have historically had limited treatment options. Additionally, positive outcomes in NSCLC have reinforced the potential of I-O in other thoracic cancers, including small cell lung cancer and mesothelioma.

Ongoing research investigating combination therapies—adding one or more agents to an I-O backbone—have yielded exciting results that highlight the promise of I-O in broader patient populations. Additionally, emerging research with biomarkers has the potential to unlock powerful tools for predicting response to I-O therapy. We anticipate that the high levels of analysis provided by the symposium will inform and benefit your clinical practice and knowledge of ongoing research efforts, and we look forward to welcoming you in Madrid!

Sincerely,
Martin Reck, MD, PhD
LungenClinic Grosshansdorf, Germany
Meeting Chair

Programme

- 13:00 | **Welcome and Introductions**
Martin Reck, MD, PhD
Germany
- 13:05 | **Current and Evolving Research Landscape for I-O in NSCLC**
Martin Reck, MD, PhD
Germany
- 13:20 | **The Evolving Treatment Paradigm for Head & Neck Cancer With I-O**
Stefan Kasper, MD
Germany
- 13:35 | **Exploring the Potential for I-O in SCLC and Mesothelioma**
Solange Peters, MD, PhD
Switzerland
- 13:45 | **Role of Biomarkers and Other Clinical Considerations**
Solange Peters, MD, PhD
Switzerland
- 13:55 | **Clinical Cases and Q&A**
Martin Reck, MD, PhD | Full Panel

Saturday, 9 September 2017 | 13:00–14:30
IFEMA, Feria de Madrid
Tarragona Auditorium, Hall 9
Madrid, Spain